In the 2016 WHO classification, mutations in isocitrate dehydrogenase (IDH) 1 and 2 are key genetic events in adult lower grade gliomas (LrGG), which include WHO grade II and grade III gliomas. The gene discussed is IDH3A; the disease is central nervous system cancer.